Vivimed Labs Limited has announced a board meeting scheduled for March 13, 2026, to review and approve the company's quarterly financial performance. The pharmaceutical company issued the formal notice on March 9, 2026, in compliance with regulatory requirements.

Board Meeting Details

The meeting specifics are outlined in the following table:

Regulatory Compliance

The notice was issued pursuant to Regulation 29 of SEBI (Listing Obligations & Disclosure Requirements), 2015. Company Secretary Yugandhar Kopparthi signed the formal communication sent to both major stock exchanges where the company's shares are listed.

Stock Exchange Communication

Vivimed Labs submitted the board meeting notice to:

• BSE Limited: Trading under code 532660
• National Stock Exchange of India Ltd: Listed as VIVIMEDLAB

The company maintains its registered office at Kolhar Industrial Area, Bidar, Karnataka, while its corporate office operates from GMR Towers, Hyderabad, Telangana. The board meeting will address the financial results and any other relevant business items as determined by the directors.

Vivimed Labs Limited has secured significant legal relief through an interim stay order from the Telangana High Court, halting all proceedings related to a Central Bureau of Investigation case and preventing State Bank of India from declaring the company's account as fraudulent.

CBI Case Details and Allegations

The Central Bureau of Investigation registered case no. RC 03(E)/2025/CBI/BSFB/BLR on November 19, 2025 against Vivimed Labs Limited and four of its directors. The company's CFO and Company Secretary received a notice dated January 27, 2026 from CBI's Banking Securities Fraud Branch, Bengaluru on January 29, 2026.

High Court Intervention and Stay Order

Following the CBI's search and seizure operations, Vivimed Labs approached the High Court for the state of Telangana at Hyderabad seeking relief. The court granted comprehensive interim protection through its order dated February 06, 2026, which the company received on February 09, 2026.

The High Court's interim stay order provides extensive protection by:

• Restraining all further proceedings pursuant to the search and seizure operations
• Preventing coercive steps against Vivimed Labs Limited and its directors
• Blocking State Bank of India's declaration of the company's account as 'fraud'
• Maintaining status quo until further orders from the High Court

Regulatory Compliance and Disclosure

Vivimed Labs has maintained transparency through multiple disclosures under SEBI Listing Regulations. The company filed corporate announcements on February 03, 2026 and February 09, 2026, describing these disclosures as being made "in terms of good corporate practice."

The company has stated it remains in full compliance with SEBI Listing Obligations and Disclosure Requirements, 2015 and all applicable circulars. The interim stay order provides crucial breathing space for Vivimed Labs as it navigates the legal proceedings while maintaining its operational activities.